We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




First-of-its-Kind Blood Test Detects Trauma-Related Diseases

By LabMedica International staff writers
Posted on 24 Apr 2025

In today’s fast-paced world, stress and trauma have unfortunately become common experiences for many individuals. More...

Continuous exposure to stress hormones can confuse the immune system, causing it to misinterpret these stress signals as threats, similar to an infection. This misinterpretation triggers an autoimmune response, where the immune system mistakenly attacks the body, resulting in a cycle of inflammation. The longer this cycle persists, the greater the damage to both mental and physical health. Studies have shown that chronic inflammation leads to oxidative stress in the brain, a condition that contributes to mental health challenges such as anxiety, depression, and other disorders. This inflammation doesn’t just affect mental health; it also leads to a range of physical conditions, including autoimmune disorders, cardiovascular diseases, and chronic pain. Essentially, unresolved trauma and prolonged stress disrupt the body’s response systems, ultimately affecting behavior, personality, and overall well-being. Now, a simple blood test can identify biological markers of trauma-induced conditions before the onset of disease.

iXpressGenes (Huntsville, AL, USA) has discovered that prolonged stress and trauma can lead to differentiated inflammation and autoimmune responses in the body. These immune responses can result in serious trauma-induced diseases, including post-traumatic stress disorder (PTSD), autoimmune conditions, chronic pain syndromes, cardiovascular diseases, and more. These conditions can be detected through specific RNA biomarkers. iXpressGenes has developed a diagnostic aid using a biomarker technology that revolutionizes early detection and prevention of PTSD, anxiety, and depression, thereby modernizing mental health care. Identifying these biomarkers may aid in preventing and treating trauma-induced diseases, such as PTSD, autoimmune disorders, and chronic pain syndromes. The company’s Trauma Autoimmune Indicator (TAI) test is a proprietary, blood-based RNA biomarker technology that helps healthcare professionals detect biological changes caused by trauma, enabling proactive prevention of trauma-related diseases.

TAI screening represents a breakthrough in trauma care by detecting trauma-induced inflammation at the cellular level before symptoms appear. By analyzing RNA and identifying specific protein dysregulations associated with immune response, TAI screening reveals the hidden changes trauma causes in the body. This early detection not only helps identify the impact of trauma but also provides valuable insights for timely intervention, reducing the risk of long-term health complications. Just like how a cholesterol test aids in preventing heart attacks and other cardiovascular conditions through early intervention, early detection of trauma-related biomarkers can help providers shift from reactive treatment to proactive prevention of trauma-induced diseases.

Related Links:
iXpressGenes


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.